Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 12.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,087,149 shares of the company’s stock after purchasing an additional 655,238 shares during the period. Geode Capital Management LLC owned about 1.56% of Recursion Pharmaceuticals worth $41,160,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock valued at $229,908,000 after purchasing an additional 9,737,196 shares in the last quarter. State Street Corp raised its position in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. Norges Bank purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $23,429,000. Charles Schwab Investment Management Inc. grew its holdings in Recursion Pharmaceuticals by 17.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company’s stock valued at $15,372,000 after buying an additional 333,323 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Recursion Pharmaceuticals by 6.1% during the third quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock worth $7,751,000 after buying an additional 67,464 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $5.64 on Wednesday. The stock’s fifty day moving average is $6.75 and its two-hundred day moving average is $6.81. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of -3.69 and a beta of 1.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. During the same period in the previous year, the firm earned ($0.42) earnings per share. The company’s revenue for the quarter was down 57.8% on a year-over-year basis. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Morgan Stanley cut their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Finally, Leerink Partners cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.20.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.